<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280318</url>
  </required_header>
  <id_info>
    <org_study_id>UCL-ONCO 2008-03</org_study_id>
    <secondary_id>Academic study</secondary_id>
    <nct_id>NCT01280318</nct_id>
  </id_info>
  <brief_title>Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery</brief_title>
  <acronym>HNSCC</acronym>
  <official_title>Profile of Plasma Growth Factors Before and After Head and Neck Oncological or Non-oncological Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The obvious hypothesis is that the application of peri-operative targeted biological agents&#xD;
      may counteract the tumor growth effect of these circulating factors and improve patient&#xD;
      outcome&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>identification of the biomarkers could lead to the development of peri-operative targeted therapies to decrease the risk of local and distant tumor growth</measure>
    <time_frame>5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the results of group I with groups II and III</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <condition>Growth Factor</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients with operable head and neck squamous cell carcinoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients treated by neck ansd head surgery for a non-oncological disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients treated before surgery with 3 doses of neoadjuvant cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>head and neck surgery</intervention_name>
    <description>Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years and over&#xD;
&#xD;
             _ histological proven squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             hypopharinx or larynx&#xD;
&#xD;
          -  Patients selected for a primary surgical treatment&#xD;
&#xD;
          -  no distant metastases&#xD;
&#xD;
          -  no active second malignancy during the last 5 years except non melanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  no prior or concurrent evidence of uncontrolled severe pathology precluding&#xD;
             administration of surgery&#xD;
&#xD;
          -  life expectancy of more than 3 months&#xD;
&#xD;
          -  not pregnant or nursing; fertile patients both male and female, must use effective&#xD;
             contraception&#xD;
&#xD;
          -  absence of any psychological, familial, sociological or geographical condition&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             conditions should be discussed with the patient before registration in the trial&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  performance status ECOG 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nasopharynx cancer&#xD;
&#xD;
          -  past or current malignancy other than HNSCC&#xD;
&#xD;
          -  performance ECOG status more than 2&#xD;
&#xD;
          -  concurrent chronic systemic immune therapy, chemotherapy, or hormone therapy not&#xD;
             indicated in the study protocol&#xD;
&#xD;
          -  use of any investigational agents within 4 weeks prior to entry&#xD;
&#xD;
          -  Previous exposure to EGFR targeting therapy&#xD;
&#xD;
          -  known grade hypersensitivity to cetuximab&#xD;
&#xD;
          -  legal incapacity or limited legal capacity or medical or psychological condition which&#xD;
             in the opiniion of the investigator would not permit the patient to complete the study&#xD;
             or sign meaningful informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pascal Machiels, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc-UCL</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean-Pascal Machiels</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>January 19, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>November 13, 2012</last_update_submitted>
  <last_update_submitted_qc>November 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

